{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:12:22Z","timestamp":1790176342141,"version":"4.1.0"},"reference-count":28,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"DOI":"10.61622\/rbgo\/2026rbgo130","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:47Z","timestamp":1774970687000},"source":"Crossref","is-referenced-by-count":1,"title":["Human papillomavirus-based vs. cytology for cervical cancer screening: a systematic review with meta-analysis"],"prefix":"10.61622","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0790-7242","authenticated-orcid":false,"given":"Kellen Crizel da","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-7849","authenticated-orcid":false,"given":"Everton Bruno","family":"Castanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5368-7533","authenticated-orcid":false,"given":"Maria Eduarda Minervino","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3848-0807","authenticated-orcid":false,"given":"Celene Maria Longo da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"47794","reference":[{"key":"key20260331152440_B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/jog.16032","article-title":"Asia Oceania Federation of Obstetrics and Gynecology (AOFOG)'s efforts in the cervical cancer elimination program in the Asia-Pacific","volume":"50","author":"Padolina","year":"2024","unstructured":"1 Padolina CS, Toral JA. Asia Oceania Federation of Obstetrics and Gynecology (AOFOG)'s efforts in the cervical cancer elimination program in the Asia-Pacific. J Obstet Gynaecol Res. 2024;50 Suppl 1:42-8. doi: 10.1111\/jog.16032","journal-title":"J Obstet Gynaecol Res"},{"issue":"10","key":"key20260331152440_B2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","unstructured":"2 Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810-9. doi: 10.7326\/0003-4819-132-10-200005160-00009","journal-title":"Ann Intern Med"},{"issue":"2","key":"key20260331152440_B3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","unstructured":"3 Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102-31. doi: 10.1097\/LGT.0000000000000525","journal-title":"J Low Genit Tract Dis"},{"issue":"5","key":"key20260331152440_B4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","unstructured":"4 Cuzick J, Clavel C, Petry K, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-101. doi: 10.1002\/ijc.21955","journal-title":"Int J Cancer"},{"issue":"2","key":"key20260331152440_B5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","unstructured":"5 Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-97. doi: 10.1016\/j.ygyno.2014.11.076","journal-title":"Gynecol Oncol"},{"issue":"51","key":"key20260331152440_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13510","article-title":"ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening","volume":"13","author":"Kitchener","year":"2009","unstructured":"6 Kitchener H, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1-150, iii-iv. doi: 10.3310\/hta13510","journal-title":"Health Technol Assess"},{"issue":"5","key":"key20260331152440_B7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans","volume":"26","author":"Maver","year":"2020","unstructured":"7 Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579-83. doi: 10.1016\/j.cmi.2019.09.006","journal-title":"Clin Microbiol Infect"},{"key":"key20260331152440_B8","volume-title":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention","author":"World Health Organization","year":"2021","unstructured":"8 World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: WHO; 2021.","edition":"2nd ed"},{"issue":"1","key":"key20260331152440_B9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41598-021-04201-y","article-title":"Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis","volume":"12","author":"Terasawa","year":"2022","unstructured":"9 Terasawa T, Hosono S, Sasaki S, Hoshi K, Hamashima Y, Katayama T, et al. Comparative accuracy of cervical cancer screening strategies in healthy asymptomatic women: a systematic review and network meta-analysis. Sci Rep. 2022;12(1):94. doi: 10.1038\/s41598-021-04201-y","journal-title":"Sci Rep"},{"issue":"8","key":"key20260331152440_B10","first-page":"CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos","year":"2017","unstructured":"10 Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8(8):CD008587. doi: 10.1002\/14651858.CD008587.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"key20260331152440_B11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","unstructured":"11 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"11","key":"key20260331152440_B12","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.7326\/M21-2234","article-title":"QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies","volume":"174","author":"Yang","year":"2021","unstructured":"12 Yang B, Mallett S, Takwoingi Y, Davenport CF, Hyde CJ, Whiting PF, et al. QUADAS-C: a tool for assessing risk of bias in comparative diagnostic accuracy studies. Ann Intern Med. 2021;174(11):1592-9. doi: 10.7326\/M21-2234","journal-title":"Ann Intern Med"},{"issue":"7650","key":"key20260331152440_B13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","unstructured":"13 Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. doi: 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"5","key":"key20260331152440_B14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ijc.34970","article-title":"Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan : The ACCESS randomized controlled trial","volume":"155","author":"Fujita","year":"2024","unstructured":"14 Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, et al. Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan : The ACCESS randomized controlled trial. Int J Cancer. 2024;155(5):905-15. doi: 10.1002\/ijc.34970","journal-title":"Int J Cancer"},{"issue":"6","key":"key20260331152440_B15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.2017.485","article-title":"Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology","volume":"118","author":"Gustavsson","year":"2018","unstructured":"15 Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand AS, Sanner K, et al. Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018;118(6):896-904. doi: 10.1038\/bjc.2017.485","journal-title":"Br J Cancer"},{"issue":"1","key":"key20260331152440_B16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"320","author":"Ogilvie","year":"2018","unstructured":"16 Ogilvie GS, Van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43-52. doi: 10.1001\/jama.2018.7464","journal-title":"JAMA"},{"issue":"11","key":"key20260331152440_B17","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/ijc.30385","article-title":"Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial","volume":"139","author":"Isidean","year":"2016","unstructured":"17 Isidean SD, Mayrand M, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer. 2016;139(11):2456-66.","journal-title":"Int J Cancer"},{"key":"key20260331152440_B18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7789","article-title":"Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland","volume":"345","author":"Leinonen","year":"2012","unstructured":"18 Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789. doi: 10.1136\/bmj.e7789","journal-title":"BMJ"},{"issue":"9806","key":"key20260331152440_B19","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(11)61522-5","article-title":"Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial","volume":"378","author":"Lazcano-Ponce","year":"2011","unstructured":"19 Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmer\u00f3n J, Uribe P, Velasco-Mondrag\u00f3n E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378(9806):1868-73. doi: 10.1016\/S0140-6736(11)61522-5","journal-title":"Lancet"},{"issue":"9","key":"key20260331152440_B20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1055-9965.EPI-22-0340","article-title":"Randomized implementation of a primary human papillomavirus testing\u2013based cervical cancer screening protocol for women 34 to 69 years in Norway","volume":"31","author":"Nyg\u00e5rd","year":"2022","unstructured":"20 Nyg\u00e5rd M, Enges\u00e6ter B, Castle PE, Berland JM, Eide ML, Iversen OE, et al. Randomized implementation of a primary human papillomavirus testing\u2013based cervical cancer screening protocol for women 34 to 69 years in Norway. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1812-22. doi: 10.1158\/1055-9965.EPI-22-0340","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"key20260331152440_B21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamaoncol.2020.6575","article-title":"Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in china: a multicenter, open-label, randomized clinical trial","volume":"7","author":"Zhang","year":"2021","unstructured":"21 Zhang J, Zhao Y, Dai Y, Dang L, Ma L, Yang C, et al. Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in china: a multicenter, open-label, randomized clinical trial. JAMA Oncol. 2021;7(2):263-70. doi: 10.1001\/jamaoncol.2020.6575","journal-title":"JAMA Oncol"},{"key":"key20260331152440_B22","doi-asserted-by":"crossref","first-page":"108031","DOI":"10.1016\/j.ypmed.2024.108031","article-title":"Lower incidence of vaginal cancer after cervical human papillomavirus screening - long-term follow-up of Finnish randomized screening trial","volume":"185","author":"Vahteristo","year":"2024;","unstructured":"22 Vahteristo M, Leinonen MK, Sarkeala T, Anttila A, Hein\u00e4vaara S. Lower incidence of vaginal cancer after cervical human papillomavirus screening - long-term follow-up of Finnish randomized screening trial. Prev Med. 2024;185:108031. doi: 10.1016\/j.ypmed.2024.108031","journal-title":"Prev Med"},{"issue":"1","key":"key20260331152440_B23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1055-9965.EPI-20-1177","article-title":"Assessing 10-year safety of a single negative HPV test for cervical cancer screening: evidence from FOCAL-DECADE Cohort","volume":"30","author":"Gottschlich","year":"2021","unstructured":"23 Gottschlich A, Van Niekerk D, Smith LW, Gondara L, Melnikow J, Cook DA, et al. Assessing 10-year safety of a single negative HPV test for cervical cancer screening: evidence from FOCAL-DECADE Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30(1):22-9. doi: 10.1158\/1055-9965.EPI-20-1177","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"key20260331152440_B24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.34039","article-title":"Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical) trial","volume":"151","author":"Gottschlich","year":"2022","unstructured":"24 Gottschlich A, Gondara L, Smith LW, Cook D, Martin RE, Lee M, et al. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical) trial. Int J Cancer. 2022;151(6):897-905. doi: 10.1002\/ijc.34039","journal-title":"Int J Cancer"},{"issue":"Pt A","key":"key20260331152440_B25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canep.2017.07.017","article-title":"CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: design, methods and baseline data of 18,471 women","volume":"50","author":"Morisada","year":"2017","unstructured":"25 Morisada T, Teramoto K, Takano H, Sakamoto I, Nishio H, Iwata T, et al. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: design, methods and baseline data of 18,471 women. Cancer Epidemiol. 2017;50(Pt A):60-7. doi: 10.1016\/j.canep.2017.07.017","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"key20260331152440_B26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0043-1763493","article-title":"Cervical cancer screening with DNA-HPV testing and precancerous lesions detection: a Brazilian population-based demonstration study","volume":"45","author":"Teixeira","year":"2023","unstructured":"26 Teixeira JC, Vale DB, Discacciati MG, Campos CS, Bragan\u00e7a JF, Zeferino LC. Cervical cancer screening with DNA-HPV testing and precancerous lesions detection: a Brazilian population-based demonstration study. Rev Bras Ginecol Obstet. 2023;45(1):21-30. doi: 10.1055\/s-0043-1763493","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"key20260331152440_B27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13224-020-01380-y","article-title":"Role of cervical cancer biomarkers p16 and ki67 in abnormal cervical cytological smear","volume":"71","author":"Gothwal","year":"2021","unstructured":"27 Gothwal M, Nalwa A, Singh P, Yadav G, Bhati M, Samriya N. Role of cervical cancer biomarkers p16 and ki67 in abnormal cervical cytological smear. J Obstet Gynecol India. 2021;71(1):72-7. doi: 10.1007\/s13224-020-01380-y","journal-title":"J Obstet Gynecol India"},{"key":"key20260331152440_B28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2023.11.036","article-title":"Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial","volume":"180","author":"Vahteristo","year":"2024","unstructured":"28 Vahteristo M, Leinonen MK, Sarkeala T, Anttila A, Hein\u00e4vaara S. Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial. Gynecol Oncol. 2024;180:146-51. doi: 10.1016\/j.ygyno.2023.11.036","journal-title":"Gynecol Oncol"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:52Z","timestamp":1774970692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/human-papillomavirus-based-vs-cytology-for-cervical-cancer-screening-a-systematic-review-with-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["10.61622\/rbgo\/2026rbgo130"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2026rbgo130","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e-rbgo130"}}